|
1
|
Betteridge DJ: Diabetic dyslipidaemia. Eur
J Clin Invest. 29(Suppl 2): S12–S16. 1999. View Article : Google Scholar
|
|
2
|
Goldberg IJ: Clinical review 124: Diabetic
dyslipidemia: Causes and consequences. J Clin Endocrinol Metab.
86:965–971. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lin J, Yang R, Tarr PT, Wu PH, Handschin
C, Li S, Yang W, Pei L, Uldry M, Tontonoz P, et al: Hyperlipidemic
effects of dietary saturated fats mediated through PGC-1beta
coactivation of SREBP. Cell. 120:261–273. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mendelson JH and Mello NK: Alcohol-induced
hyperlipidemia and beta lipoproteins. Science. 180:1372–1374. 1973.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Dunn FL: Hyperlipidemia in diabetes
mellitus. Diabetes Metab Rev. 6:47–61. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Karthick N, Dillara K, Poornima KN and
Subhasini AS: Dyslipidaemic changes in women with subclinical
hypothyroidism. J Clin Diagn Res. 7:2122–2125. 2013.PubMed/NCBI
|
|
7
|
Borba EF and Bonfá E: Dyslipoproteinemias
in systemic lupus erythematosus: Influence of disease, activity,
and anticardiolipin antibodies. Lupus. 6:533–539. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sentí M, Romero R, Pedro-Botet J, Pelegrí
A, Nogués X and Rubiés-Prat J: Lipoprotein abnormalities in
hyperlipidemic and normolipidemic men on hemodialysis with chronic
renal failure. Kidney Int. 41:1394–1399. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
O'Keefe JH and Bell DS: Postprandial
hyperglycemia/hyperlipidemia (postprandial dysmetabolism) is a
cardiovascular risk factor. Am J Cardiol. 100:899–904. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Haffner SM: Diabetes, hyperlipidemia, and
coronary artery disease. Am J Cardiol. 83:17F–21F. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
O'Brien T, Nguyen TT and Zimmerman BR:
Hyperlipidemia and diabetes mellitus. Mayo Clin Proc. 73:969–976.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Farnier M and Davignon J: Current and
future treatment of hyperlipidemia: The role of statins. Am J
Cardiol. 82:3J–10J. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Staels B, Dallongeville J, Auwerx J,
Schoonjans K, Leitersdorf E and Fruchart JC: Mechanism of action of
fibrates on lipid and lipoprotein metabolism. Circulation.
98:2088–2093. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Garg A and Grundy SM: Nicotinic acid as
therapy for dyslipidemia in non-insulin-dependent diabetes
mellitus. JAMA. 264:723–726. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ast M and Frishman WH: Bile acid
sequestrants. J Clin Pharmacol. 30:99–106. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Akoglu H, Yilmaz R, Kirkpantur A, Arici M,
Altun B and Turgan C: Combined organ failure with combination
antihyperlipidemic treatment: A case of hepatic injury and acute
renal failure. Ann Pharmacother. 41:143–147. 2007. View Article : Google Scholar
|
|
17
|
Thompson PD, Clarkson P and Karas RH:
Statin-associated myopathy. JAMA. 289:1681–1690. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Miettinen TA, Taskinen MR, Pelkonen R and
Nikkilä EA: Glucose tolerance and plasma insulin in man during
acute and chronic administration of nicotinic acid. Acta Med Scand.
186:247–253. 1969. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ho YP, To KK, Au-Yeung SC, Wang X, Lin G
and Han X: Potential new antitumor agents from an innovative
combination of demethylcantharidin, a modified traditional Chinese
medicine, with a platinum moiety. J Med Chem. 44:2065–2068. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hsu CL, Wu CH, Huang SL and Yen GC:
Phenolic compounds rutin and o-coumaric acid ameliorate obesity
induced by high-fat diet in rats. J Agric Food Chem. 57:425–431.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Park SH, Ko SK, Choi JG and Chung SH:
Salicornia herbacea prevents high fat diet-induced hyperglycemia
and hyperlipidemia in ICR mice. Arch Pharm Res. 29:256–264. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chang XX, Yan HM, Xu Q, Xia MF, Bian H,
Zhu TF and Gao X: The effects of berberine on hyperhomocysteinemia
and hyperlipidemia in rats fed with a long-term high-fat diet.
Lipids Health Dis. 11:862012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Feng Q, Gou XJ, Meng SX, Huang C, Zhang
YQ, Tang YJ, Wang WJ, Xu L, Peng JH and Hu YY: Qushi huayu
decoction inhibits hepatic lipid accumulation by activating
AMP-Activated protein kinase in vivo and in vitro. Evid Based
Complement Alternat Med. 2013:1843582013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Khin-Maung-U, Myo-Khin, Nyunt-Nyunt-Wai,
Aye-Kyaw and Tin-U: Clinical trial of berberine in acute watery
diarrhoea. Br Med J (Clin Res Ed). 291:1601–1605. 1985. View Article : Google Scholar
|
|
25
|
Akhter MH, Sabir M and Bhide NK:
Anti-inflammatory effect of berberine in rats injected locally with
cholera toxin. Indian J Med Res. 65:133–141. 1977.PubMed/NCBI
|
|
26
|
Amin AH, Subbaiah TV and Abbasi KM:
Berberine sulfate: Antimicrobial activity, bioassay, and mode of
action. Can J Microbiol. 15:1067–1076. 1969. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lin CC, Ng LT, Hsu FF, Shieh DE and Chiang
LC: Cytotoxic effects of Coptis chinensis and Epimedium sagittatum
extracts and their major constituents (berberine, coptisine and
icariin) on hepatoma and leukaemia cell growth. Clin Exp Pharmacol
Physiol. 31:65–69. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Fu Y, Hu B, Tang Q, Fu Q, Zhang Q and
Xiang JZ: Effect of jatror-rhizine, berberine, Huanglian Decoction
and compound-mimic prescription on blood glucose in mice. Chung
Tsao Yao Tsa Chih Pien Chi Pu. 36:548–551. 2005.In Chinese.
|
|
29
|
Wu H, He K, Wang Y, Xue D, Ning N, Zou Z,
Ye X, Li X, Wang D and Pang J: The antihypercholesterolemic effect
of jatrorrhizine isolated from Rhizoma Coptidis. Phytomedicine.
21:1373–1381. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Fu Y, Hu B, Tang Q, Fu Q and Xiang J:
Hypoglycemic activity of jatrorrhizine. J Huazhong Univ Sci
Technolog Med Sci. 25:491–493. 2005. View Article : Google Scholar
|
|
31
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
32
|
Saltiel AR and Kahn CR: Insulin signalling
and the regulation of glucose and lipid metabolism. Nature.
414:799–806. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kopelman PG: Obesity as a medical problem.
Nature. 404:635–643. 2000.PubMed/NCBI
|
|
34
|
Toth PP: Cardiology patient page. The
'good cholesterol': High-density lipoprotein. Circulation.
111:e89–e91. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wiegman CH, Bandsma RH, Ouwens M, van der
Sluijs FH, Havinga R, Boer T, Reijngoud DJ, Romijn JA and Kuipers
F: Hepatic VLDL production in ob/ob mice is not stimulated by
massive de novo lipogenesis but is less sensitive to the
suppressive effects of insulin. Diabetes. 52:1081–1089. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Liu F, Li Z, Shi X and Zhong M:
Determination of berberine, palmatine and jatrorrhizine in rabbit
plasma by liquid chromatography-electrospray ionization-mass
spectrometry. J Pharm Biomed Anal. 56:1006–1015. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kong W, Zhao Y, Xiao X, Jin C, Liu Y and
Li Z: Comparison of anti-bacterial activity of four kinds of
alkaloids in Rhizoma Coptidis based on microcalorimetry.
Zhongguohuaxue (yingwenban). 27:1186–1190. 2009.In Chinese.
|
|
38
|
Liu R, Cao Z, Pan Y, Zhang G, Yang P, Guo
P and Zhou Q: Jatrorrhizine hydrochloride inhibits the
proliferation and neovascularization of C8161 metastatic melanoma
cells. Anticancer Drugs. 24:667–676. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Xiong C and Fang D: Effects of
jatrorrhizine on isolated guinea pig atria. Zhongguo Yaolixue Yu
Dulixue Zazhi. 4:255–259. 1989.In Chinese.
|
|
40
|
Reddy JK and Rao MS: Lipid metabolism and
liver inflammation. II. Fatty liver disease and fatty acid
oxidation. Am J Physiol Gastrointest Liver Physiol. 290:G852–G858.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Renner EL and Dällenbach A: Increased
liver enzymes: What should be done? Ther Umsch. 49:281–286. 1992.In
German. PubMed/NCBI
|
|
42
|
Nguyen P, Leray V, Diez M, Serisier S, Le
Bloc'h J, Siliart B and Dumon H: Liver lipid metabolism. J Anim
Physiol Anim Nutr (Berl). 92:272–283. 2008. View Article : Google Scholar
|
|
43
|
Eberlé D, Hegarty B, Bossard P, Ferré P
and Foufelle F: SREBP transcription factors: Master regulators of
lipid homeostasis. Biochimie. 86:839–848. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Janani C and Ranjitha Kumari BD: PPAR
gamma gene-A review. Diabetes Metab Syndr. 9:46–50. 2015.
View Article : Google Scholar
|
|
45
|
Pawlak M, Lefebvre P and Staels B:
Molecular mechanism of PPARα action and its impact on lipid
metabolism, inflammation and fibrosis in non-alcoholic fatty liver
disease. J Hepatol. 62:720–733. 2015. View Article : Google Scholar
|
|
46
|
Wakil SJ and Abu-Elheiga LA: Fatty acid
metabolism: Target for metabolic syndrome. J Lipid Res. 50(Suppl):
S138–S143. 2009. View Article : Google Scholar :
|
